Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA denies EUA for COVID-19 indication of SSRI fluvoxamine

By Brian Buntz | May 18, 2022

Fluvoxamine

[Fluvoxamine image from Wikipedia]

The infectious disease physician-scientist Dr. David R Boulware filed for the emergency use authorization (EUA) of fluvoxamine, an established selective serotonin reuptake inhibitor (SSRI) whose brand name is Luvox.

The FDA has rejected the application, explaining the COVID-19 treatment benefit of the drug was “not persuasive” in the TOGETHER study that was the basis of the EUA application. 

The randomized, double-blind study had a composite endpoint consisting of a reduction of emergency room visits due to worsening COVID-19 infection and hospitalization resulting from COVID-19 up to 28 days after randomization. 

The study concluded that fluvoxamine reduced COVID-19 hospitalizations by as much as 30%.

Although the study met its primary endpoint, FDA noted that “the results were primarily driven by a reduction in the emergency department visits lasting greater than 6 hours.” 

The agency added that “there are uncertainties about assessing this endpoint” and questioned whether the 6-hour time threshold was “a clinically meaningful threshold.”   

FDA went on to raise doubts about the design of the TOGETHER study.

Finally, the agency noted that two other trials, known as STOP COVID 2 and COVID-OUT, “failed to demonstrate a benefit with fluvoxamine in adults with mild COVID-19 in the outpatient setting, and both were terminated early for futility.”

In 1994, fluvoxamine became the first FDA-approved SSRI. 

The logic for using the drug for COVID-19 is that it inhibits the sigma-1 receptor (SR1) associated with inflammation, which influences the body’s COVID-19 response. 

It was developed by Kali-Dupha, part of Solvay Pharmaceuticals, which Abbott Laboratories acquired for €4.5 billion in 20210. 

It is currently FDA-approved for treating obsessive-compulsive disorder in individuals at least 8 years old. 

Boulware responded to FDA critiquing the consistency of the agency’s definition of “hospitalization” for new drugs such as the COVID-19 antiviral Paxlovid from Pfizer compared to generic drugs.

In an interview with MedPage Today, Boulware observed that Merck & Co.’s molnupiravir appeared to have similar treatment efficacy as fluvoxamine, which was authorized for emergency use. 

Boulware filed for emergency use authorization before FDA authorized the use of the COVID-19 antivirals molnupiravir and Plaxovid. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE